- In March 2025, Alnylam Pharmaceuticals, Inc. received FDA approval for AMVUTTRA (vutrisiran) in treating transthyretin-mediated cardiomyopathy (ATTR‑CM), making it the first RNAi therapeutic targeting both cardiomyopathy and polyneuropathy in amyloidosis. This significant milestone is expected to expand the therapy’s market and improve patient access
- In March 2025, Alnylam's Qfitlia (fitusiran), an siRNA therapeutic for hemophilia A and B (with or without inhibitors), received FDA approval, becoming the first RNAi drug to directly reduce bleeding rates in hemophilia patients
- In February 2025, At its R&D Day in New York City, Alnylam announced progress on multiple next-generation RNAi candidates, including its nucresiran Phase 3 trial (TRITON) targeting ATTR‑CM, alongside advancements in cardiovascular and neuroscience pipelines
- In January 2025, Alnylam reported record net product revenues of USD 1.646 billion for 2024 (33% YoY growth), driven by strong sales of Onpattro, Amvuttra, Givlaari, and Oxlumo, and guided to over USD 2 billion in 2025
